Arcutis Expands Access with Virtual Health Platform for Chronic Skin Diseases
Event summary
- Arcutis launched a virtual health platform on June 30, 2026, to improve access to care for patients with chronic inflammatory skin diseases.
- The platform connects patients with independent, board-certified dermatologists for evaluation and treatment discussions.
- ZORYVE (roflumilast) prescriptions are coordinated through a national pharmacy hub or sent to preferred pharmacies.
- The platform aims to complement traditional in-office dermatology care by reducing barriers such as long wait times and geographic limitations.
The big picture
Arcutis' virtual health platform launch aligns with broader industry trends toward digital health solutions, aiming to address access barriers in dermatology care. The platform complements traditional care settings by offering a convenient alternative for patients struggling with timely dermatology appointments. This strategic move positions Arcutis to capture a larger share of the chronic inflammatory skin disease market, which affects over 45 million people in the U.S.
What we're watching
- Adoption Rate
- The pace at which patients and dermatologists adopt the virtual health platform will determine its success in expanding access to care.
- Regulatory Compliance
- Whether Arcutis can maintain compliance with evolving healthcare regulations while scaling the platform.
- Market Differentiation
- How the virtual health platform will differentiate Arcutis in a competitive dermatology market.